REG - Genus - PRRS Resistant Pig – FDA Approval

GenusAnnouncement

Yesterday 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250430:nRSd7144Ga&default-theme=true

RNS Number : 7144G  Genus PLC  30 April 2025

30 April 2025

Genus plc ("Genus" or the "Group")

PRRS Resistant Pig - FDA Approval

Genus (LSE: GNS), a leading global animal genetics company, announces the
following update in relation to its innovative PRRS(1) Resistant Pig ("PRP")
programme.

Genus is pleased to announce that the U.S. Food and Drug Administration
("FDA") has approved the PRP gene edit for use in the U.S. food supply chain,
in line with expectations. This landmark approval follows years of close
collaboration with the FDA and is a significant step on the pathway to PRP
commercialisation in the U.S.. Genus believes successful U.S.
commercialisation also requires approvals in key U.S. export markets, being
Mexico, Canada and Japan. The Group continues to make progress with regulators
in these jurisdictions as well as with other international regulators,
including China.

Brazil, Colombia and, more recently, the Dominican Republic have already
issued positive determinations for PRP, meaning those countries will regulate
the PRP the same as any other pigs.

PRRS is one of the most devastating global pig diseases and causes suffering
and premature death for pigs. Recent research indicates that PRRS also
increases the need for antibiotics by more than 200%(2).

"We have spent years conducting extensive research, validating our findings
and working with the FDA to gain approval" said Matt Culbertson, Genus PIC's
Chief Operating Officer. "Today marks a major milestone for the pork
industry."

"FDA approval is a fantastic achievement for Genus PIC and represents a major
step towards U.S. commercialisation. We will now continue to pursue regulatory
approvals in other international jurisdictions with a focus on key U.S. export
markets" said Jorgen Kokke, Genus's Chief Executive Officer.

For further information please contact:

Genus plc                            Tel: +44 125
634 5970

Jorgen Kokke, Chief Executive Officer

Alison Henriksen, Chief Financial Officer

Anand Date, Investor Relations & Sustainability Director

Burson Buchanan             Tel: +44 207 466 5000

Charles Ryland; Toto Berger; Sophie Wills; Verity Parker

About Genus

Genus is a world-leading animal genetics company. Genus creates advances in
animal breeding and genetic improvement by applying biotechnology and sells
added value products for livestock farming and food producers. Its technology
is applicable across livestock species and is currently commercialised by
Genus in the dairy, beef and pork food production sectors.

Genus's worldwide sales are made in over seventy-five countries under the
trademarks 'ABS' (dairy and beef cattle) and 'PIC' (pigs) and comprise semen,
embryos and breeding animals with superior genetics to those animals currently
in farms. Genus's customers' animals produce offspring with greater production
efficiency, and quality, and use these to supply the global dairy and meat
supply chains.

The Group's competitive edge has been created from the ownership and control
of proprietary lines of breeding animals, the biotechnology used to improve
them and its global supply chain, technical service and sales and distribution
network. The PRP is a market leading innovation in gene editing, which Genus
is looking to commercialise in the porcine industry once regulatory approval
is gained.

With headquarters in Basingstoke, United Kingdom, Genus companies operate in
over twenty-five countries on six continents, with research laboratories
located in Madison, Wisconsin, USA.

(1) Porcine Reproductive and Respiratory Syndrome

(2) Assessment of changes in antibiotic use in grow-finish pigs after the
introduction of PRRSV in a naïve farrow-to-finish system
(https://dr.lib.iastate.edu/entities/publication/4e3cd302-5ae9-4185-8ead-405e0d4ec2f2)
(Machado et al, Iowa State University, 2023)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCPPUWGCUPAGBB